Phillipe Moreau, MD | Authors


Responses Improved for Newly Diagnosed Myeloma in Phase III CASSIOPEIA Trial

July 11, 2019

Phillipe Moreau, MD, discusses the results from the randomized, open-label, multicenter phase III CASSIOPEIA trial. The results of the trial led to a priority review designation from the FDA for the combination of daratumumab plus bortezomib, thalidomide, and dexamethasone for patients with treatment-naïve multiple myeloma who are candidates for autologous stem cell transplant.